Trials / Completed
CompletedNCT05409924
First-in-human Single and Multiple Dose Trial of ATR-258
The ATTRACTIVE 1 Trial - a First-in-human Phase I, Dose Escalating, Double-blind, Placebo-controlled, Single and Multiple Dose Trial of ATR-258 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Atrogi AB · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a single-site, randomized, double-blinded, placebo-controlled, First-in-Human trial, conducted in 3 parts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATR-258 | Single Ascending Dose |
| DRUG | ATR-258 | Multiple Ascending Dose |
| DRUG | ATR-258 | Repeat Dose |
Timeline
- Start date
- 2022-04-11
- Primary completion
- 2023-10-04
- Completion
- 2023-10-04
- First posted
- 2022-06-08
- Last updated
- 2023-12-18
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05409924. Inclusion in this directory is not an endorsement.